• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Beau Lines

News
Article

Transverse depressions like the one shown here appeared on all the other nails of this 68-year-old man several weeks after he had suffered a myocardial infarction.

 

Transverse depressions like the one shown here appeared on all the other nails of this 68-year-old man several weeks after he had suffered a myocardial infarction. Beau lines are associated with any severe disability that temporarily interferes with the rate of nail growth, such as infectious disease or myocardial infarction. Patients can be reassured that as the nail grows out so, too, will the deformity, until it eventually resolves.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

Patient Care Staff
January 15th 2025
Article

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Grace Halsey
January 10th 2025
Article

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose / image credit: ©New Africa/AdobeStock

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose

Sydney Jennings
January 8th 2025
Article

Your daily dose of the clinical news you may have missed.

Bird Flu: First US Death Reported, NIH Updates Risk Assessment

Bird Flu: First US Death Reported, NIH Updates Risk Assessment

John Parkinson;Grace Halsey
January 7th 2025
Article

The first death of an American from the H5N1 virus was reported in Louisiana on Monday, though authorities maintain the risk of widespread infection remains low.

© 2025 MJH Life Sciences

All rights reserved.